BMI View: China will become a leading medical research hub within the Asia Pacific region. This will be
largely led by multinational pharmaceutical firms as they seek to tap the large talent pool within the
country and develop treatments 'in China, for China'. The loc ..."
BMI View: Ongoing challenges facing multinational pharmaceutical firms in China will persist into 2016.
This includes pricing pressures on off-patented pharmaceuticals, as authorities look to meet the unmet
medical need in the country by expanding access to medicines ..."
BMI View: The merger of China's new rural cooperative medical scheme with its urban residents basic
medical insurance scheme will reshape the country's healthcare landscape. This will have important
ramifications for the pharmaceutical industry as reimbursement models ..."
BMI View: Provincial and county level healthcare markets in China will become increasingly important for multinational pharmaceutical companies. This follows government reforms to channel patient volumes to local medical facilities as well as the saturation of the major hospital ..."
BMI View: The policy changes affecting China's pharmaceutical market will not deter the growth
trajectory of local drugmakers. While competition has heightened due to the new tendering system, the
system will remain more favourable to Chinese drugmakers as their produ ..."
BMI View: Multinational pharmaceutical companies will continue to invest and grow their presence in
China, despite the slowdown in the economy. Driving this outlook is the outperformance of the
pharmaceutical sector as authorities continue to improve healthcare access ..."
BMI View: Pharmaceutical sales in China will continue to grow robustly - boosted by the improvement in
healthcare access, liberalisation of the industry as well as an epidemiological transition towards chronic
diseases. This will present strong revenue earning opportu ..."
BMI View: Improvements in intellectual property protection, an ageing population and increasing access
to healthcare will drive the robust growth of China's pharmaceutical market. This will attract foreign drug
manufacturers despite the downside risks of pharmaeconomi ..."
BMI View: Cuba has been making tacit admissions of major structural changes to reform its economy, and
seeking greater inclusion in the global economy. We therefore believe that the local pharmaceutical
sector will outpace other industries and present significant oppo ..."
BMI View: In line with our optimism towards the Chinese healthcare sector, many multinational
pharmaceutical firms continue to record healthy double-digit revenue growth in Q114, despite the economic
slowdown. Given the attractiveness of the Chinese pharmaceutical mar ..."